In the past, cardiologists and neurologists tended to vote along party lines in the debate over closure devices vs. medical management of patients with a patent foramen ovale (PFO).

Improving efficiencies and patient outcomes in the cath lab can go hand in hand. 

As the Affordable Care Act continues rolling out, preventable readmissions will cost hospitals even more. 

The release of four prevention guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA) raised eyebrows, particularly over the use of a new cardiovascular risk calculator and the abandonment of number targets for cholesterol management. 

With transcatheter aortic valve replacement (TAVR), proper patient selection plays a key role in successful outcomes. 

For men and women living with post-traumatic stress disorder (PTSD), their bodies may be as profoundly affected as their minds.

Patients who develop STEMI in the hospital may fare considerably worse than patients who experience one outside the hospital and arrive via ambulance or get driven, a study published online Jan. 3 in Circulation found. Treatment time and length of stay after an in-hospital STEMI are longer and mortality is higher, the authors found.

CSL Behring today announced that Kcentra® (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA) approval for an expanded indication -- urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients needing an urgent surgery or other invasive procedure. Kcentra, approved by the FDA in April 2013 for the urgent reversal of warfarin therapy in adult patients with acute major bleeding, is the only non-activated 4-factor prothrombin complex concentrate (4F-PCC) indicated in the U.S. for these uses.